1.Clinical Observation of Trantuzumab Combined with Preoperative Adjuvant Chemotherapy in the Treatment of Her-2 Positive Breast Cancer
China Pharmacy 2015;(29):4104-4106,4107
OBJECTIVE:To observe the effect of trantuzumab combined with preoperative adjuvant chemotherapy in the treat-ment of human epidermal growth factor receptors 2 (Her-2) positive breast cancer,and to investigate its clinical value. METH-ODS:80 patients with Her-2 positive breast cancer were selected and randomly divided into observation group and control group, with 40 cases in each group. The control group received routine preoperative adjuvant chemotherapy+modified radical mastectomy for Her-2 positive breast cancer;observation group was additionally treated with trastuzumab intravenously before operation,initial dose of 4 mg/kg,followed by 2 mg/kg,once a week,for consecutive 3 weeks,on the basis of control group. The effects of two regimen on the expression of HER-2,CD-34,MGA,E-cadherin and GCDFE-15 in Her 2 positive breast cancer focus were com-pared between 2 groups. ADR and follow-up survey were recorded. RESULTS:Compared with before chemotherapy,the expres-sion of HER-2(+)in observation group increased significantly,while that of HER-2(+ + +)decreased significantly;MGA posi-tive rate and GCDFP-15 positive rate decreased significantly while E-cadherin positive rate increased significantly;MDV of CD34 expression decreased significantly,with statistical significance(P<0.05 or P<0.01). Relapse rate and distance transport rate of ob-servation group were significantly lower than those of control group,with statistical significance(P<0.05). There was no statisti-cal significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Trastuzumab combined with preoperative adjuvant chemotherapy have good clinical efficacy and safety,and it can effectively reduce related indicator of Her-2 positive breast cancer focus. So it has positive significance in reducing recurrence and metastasis of breast cancer.
2.Clinical meanings of serum CA19-9 level in hepatocirrhosis patients
Xuezhen HUANG ; Hong SUI ; Juhui DENG
Chinese Journal of Primary Medicine and Pharmacy 2008;15(7):1139-1140
Objective To explore the clinical meanings of serum CA19-9 levd in hepatocirrhosis patients. Methods 61 hepatitis B and hepatocirrhosis patients were as treatment group, and 35 normal were as control group. The content of serum CA19-9 was measured by dectrochemistry lighting and the liver function was determined too. According to Child-Pugh liver function integral method,the treatment group was divided into 27 cases of A grade,20 cases of B grade and 14 cases of C grade. Results The serum CA19-9 level in hepatocirrhosis patients was higher than that of normal group significantly(P< 0. 005 ). The serum CA19-9 level decreaed obviously through the treat- ment,thereinto A and B grade fell evidendy in the Child-Pugh liver function integral method( P < 0. 005). C grade was not significantly different(P<0.05 ). The serum CA19-9 levd was positivdy associated with TBiL, ALT and AST of liver function integral method. Conclusion The serum CA19-9 levd of hepatocirrhosis patients is improved in different degrees. And it can be a prognostic target and used to estimate the degree of damage of liver function of hepatocirrhosis patients.
3.A cDNA microarray study on differentially expressed genes in prostate cancer
Liqun ZHOU ; Xuezhen YANG ; Xiao HUANG
Chinese Journal of Urology 1994;0(02):-
Objective To detect differentially expressed genes in prostate cancer by cDNA microarray. Methods Total RNA was isolated by one step protocol from prostate cancer (CaP) and from normal prostate,and Poly(A) +RNA was further purified through Oligitex mRNA Midi Kit.Then it was analysed for differentially expressed genes in CaP and normal prostate by cDNA microarray with 4 096 human genes. Results There were 341 differentially expressed genes between CaP and normal prostate,of which there were 128 down regulated and 213 up regulated ones for CaP. Among these genes,15 were the most significant with 6 down regulated and 9 up regulated. Conclusions cDNA microarray can be used effectively to find out differentially expressed genes in prostate cancer which is not regulated by any single gene.Many different kinds of genes are involved in the initiation and evolution of CaP carcinogenisis.
4.Food intolerance-related symptoms in 903 individuals
Qiqin JIANG ; He HUANG ; Jing ZHENG ; Xuezhen CHEN ; Hong LI
Chinese Journal of Health Management 2011;05(5):295-298
Objective To investigate the symptoms and affecting factors of food intolerance among 903 adults.Methods Food special antibody(IgG)in human serum were examined by ELISA.Food Intolerance Health Assessment Questionnaire was used to assess positive rate of food intolerance and food intake habits.Chi-square test and Mann-Whitney test were used for data analysis.Results The ratio of food intolerance was 0.33% to 28.13%.Intolerant foods include crab(28.13%),yolk(27.02%),milk (13.07%),soybean(11.96%),shrimp,tomato,corn,beef,rice,chicken,mushroom,wheat,and pork.The symptoms of nervous system(55.89%),digestive system(45.69%)and respiratory system(15.64%)were commonly seen.Prevalence of food intolerance in mental labors was lower than manual labors.Conclusion The most common intolerant food includes crab,yolk and milk.The symptoms of food intolerance are different.Manual labors are more susceptible to food intolerance.
5.A Study on the Sedative and Hypnotic Effects of Ganoderma lucidum Brewage
Guiying HUANG ; Jiuyao ZHOU ; Huifang LIAO ; Xuezhen LIAO
Traditional Chinese Drug Research & Clinical Pharmacology 1993;0(04):-
Objective To investigate the sedative and hypnotic effects of Ganoderma lucidum brewage(GLB).Methods The NIH mice were given with gavage of GLB 0.06,0.12,and 0.24g/kg per day respectively for 15 days.The spontaneous motion,the sleeping time induced by pentobarbital sodium in subthreshold dosage and threshold dosage,and the number of mice subjected to pentylenetetrazol-induced convulsion were observed.Results GLB can reduce the spontaneous motion,significantly longthen the mice sleeping time of pentobarbital sodium in threshold dosage and increase the number of sleeping mice under subthreshold dosage of pentobarbital sodium.GLB was synergic with pentobarbital sodium,and antagonized pentylenetetrazol-induced convulsion in a dose-dependent manner.Conclusion GLB possesses obvious sedative,hypnotic and anticonvulsive effects.
6.Multicenter Study on Serum Amyloid A Protein, High-Sensitivity C-Reactive Protein and Procalcitonin in Combining Diagnosis of Infection in Different Population from Guangdong
Qiang LUO ; Zhenjie LIU ; Ning XU ; Weihong ZHANG ; Yanfen HUANG ; Dongli MA ; Peng ZHANG ; Yan LONG ; Xuezhen WU ; Xiongyan XUE
Journal of Modern Laboratory Medicine 2015;(4):39-42
Objective To evaluate combined effect on different population through 2 459 data of SAA,hs-CRP and PCT from 8 three-level hospitals in Guangdong region.Methods Subjects were divided into five groups by ages,and every group had bacterial and virus type.In order to confirm diagnostic effect on infection,methods were performed including in tendency of SAA and hs-CRP,Paired t test between bacterial and virus group,efficiency of 3 indexes in judging infection depending on ROC and parameters,multiple logistic regression,consistency between positive bacterial infection and bacterial culture.Re-sults There were statistically significant differences in SAA and hs-CRP between bacterial and virus in infants and children (P <0.001).SAA had the biggest AUC area 0.824 with sensibility 71.8% and specificity 82.6% in younger group.Corre-sponding,hs-CRP had the biggest area 0.806 with sensibility 84%.There was the accuracy of 78.8% for differential diagno-sis in younger group,while 65.1% in elder group.AUC of SAA was 0.883 for positive bacterial culture with sensibility 71.2% and specificity 90.7%,accuracy of 95.2% for differential diagnosis.Conclusion There was obvious trend of age in SAA and hs-CRP,3 indexes could be used for differential diagnosis alone or combined,especially in younger group.SAA is the best index as a separated index.There is less value at ratio of SAA and hs-CRP.
7.Clinical observastion of Bushen-Qiangjin capsule and calcium D on aromatase inhibitors-induced osteopenia in breast cancer patients
Suwen ZOU ; Zhitao GUO ; Ying ZHONG ; Xuezhen LI ; Yingfei HUANG
International Journal of Traditional Chinese Medicine 2018;40(6):507-509
Objective To observe the clinical effect of the Bushen-Qiangjin capsule and calcium D in the treatment of aromatase inhibitors-associated bone loss (AIBL) in breast cancer patients. Methods A total of 65 patients were randomized into a treatment group and a control group, 32 in the control group taking calcium D, and 33 in the treatment group taking calcium D and Bushen-Qiangjin capsule. After a 3-month treatment, the bone mineral density T (BMD), bone-specific alkaline phosphatase (BALP), bone gla protein (BGP) and tartrate resistant acid phosphatase (TrACP) of two groups were evaluated. Results The BMD increased significantly after treatment in both groups (P<0.05), and the therapeutic efficacy of the treatment group was better than of the control group (P<0.05). After treatment, the level of BALP (308.76 ± 10.99 U/L vs. 280.00 ± 7.44 U/L, t=8.170) and the BGP (42.21 ± 3.04 ng/ml vs. 34.38 ± 2.06 ng/ml, t=6.818) of the treatment group were significantly higher than those of the control group (P<0.01). The level of TrACP decreased significantly after treatment in both groups (P<0.05), and the TrACP (60.12 ± 4.58 U/L vs. 67.25±4.06 U/L, t=1.653) of treatment group was significantly lower than that of the control group (P<0.05). Conclusions The Bushen-Qiangjin capsule can produce a content efficacy in treating AIBL in breast cancer patients, improving the BMD and bone metabolism.
8.Identification of a critical region on chromosome 4p16.3 for Wolf-Hirschhorn syndrome-associated fetal growth retardation.
Wenting ZHENG ; Baojiang CHEN ; Zhijun YIN ; Xuezhen HUANG ; Yingliang LIANG
Chinese Journal of Medical Genetics 2020;37(7):731-735
OBJECTIVE:
To analyze ultrasonographic finding in fetuses with Wolf-Hirschhorn syndrome (WHS) and refine the critical region on chromosome 4p16.3 for WHS-associated fetal growth retardation (FGR).
METHODS:
In total 2262 fetuses with abnormal ultrasonographic findings who underwent prenatal karyotyping and chromosomal microarray analysis were reviewed. WHS-associated 4p deletions detected in these fetuses were compared, and prenatal ultrasound findings in such fetuses were summarized. Meanwhile, WHS cases with prenatal ultrasound findings and isolated 4p deletions in previous studies were included for further analysis. An analysis of smallest region of overlap (SRO) among discrepant 4p deletions in these cases above was performed to define a critical region for FGR.
RESULTS:
4p deletions were detected in 10 of the 2262 fetuses and 5.0% of the 202 fetuses with FGR. Combined with 80 WHS cases from previous studies, the most common prenatal ultrasound finding was FGR, which yielded a frequency of 76.7%. In addition, a SRO spanning approximately 419 kb (genomic position: 1.32-1.74 Mb) on chromosome 4p16.3 was discovered by comparing the unusual 4p deletions among the 10 fetuses. The region contained seven protein-coding genes, including TACC3, SLBP, TMEM129, FAM53A, MAEA, UVSSA and CRIPAK.
CONCLUSION
For fetuses with WHS, the most common prenatal ultrasound phenotype was FGR. A region between 1.32 Mb to 1.74 Mb from the telomere on chromosome 4p16.3 is critical for WHS-associated FGR, for which TACC3 and SLBP are the candidate genes.
9.Values of combined detection of polygene methylation in stool for the diagnosis of colorectal cancer and precancerous lesions
Ziyi HUANG ; Yanxin HE ; Cunhai CHEN ; Peng ZHAO ; Weihong SUN ; Chengcheng DAI ; Zhiqian WANG ; Jie LI ; Zifan WANG ; Zheng WANG ; Jiahui JIN ; Tongsong ZHANG ; Xuezhen MA
Cancer Research and Clinic 2022;34(4):248-254
Objective:To investigate the methylation status of SDC2, PPP2R5C and ADHFE1 genes in stool and their values in the screening of colorectal cancer and precancerous lesions.Methods:From August 2020 to March 2021, 64 patients with colorectal cancer, 72 patients with adenoma, 33 patients with hyperplastic polyps and 59 healthy people were recruited from Qingdao Central Hospital Affiliated to Qingdao University, and the morning stool samples were collected from the research subjects. The genomic DNA was extracted and modified with sulfite. The methylation status of SDC2, PPP2R5C and ADHFE1 genes were detected by methylation specific polymerase chain reaction (MSP), and the fecal occult blood test (FOBT) was performed. Taking the pathological results as the gold standard, receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to compare the effect of combined detection of methylation of three genes and FOBT in predicting colorectal cancer and precancerous lesions. R-Studio software was used to construct a nomogram for the prediction of colorectal cancer with combined detection of gene methylation in stool and other clinical features, and the calibration and validation were performed.Results:The positive rates of combined detection of methylation of SDC2, PPP2R5C and ADHFE1 genes in stool were higher than those of FOBT in colorectal cancer+adenoma [74.3% (101/136) vs. 47.1% (64/136), χ2 = 23.20, P = 0.001], colorectal cancer [90.6% (58/64) vs. 70.3% (45/64), χ2 = 8.91, P = 0.003] and adenoma [59.7% (43/72) vs. 26.4% (19/72), χ2 = 14.43, P = 0.002]. There was no significant difference in the positive rates in hyperplastic polyps [21.2% (7/33) vs. 6.1% (2/33), χ2 = 0.12, P = 0.125] and healthy controls [10.2% (6/59) vs. 8.5% (5/59), χ2 = 4.01, P = 1.000]. The combined detection of gene methylation was better than FOBT in the prediction of colorectal cancer + adenoma [AUC: 0.85 (95% CI 0.80-0.91) vs. 0.71 (95% CI 0.64-0.78), P < 0.05], especially in the prediction of adenoma [AUC: 0.82 (95% CI 0.74-0.89) vs 0.64 (95% CI 0.57-0.69), P < 0.001]. The sensitivity and specificity of ADHFE1 gene methylation status in predicting colorectal cancer were high (90.6% and 96.6%). In colorectal cancer patients over 50 years old, the positive rate of combined detection of gene methylation was higher than that of FOBT [90.2% (55/61) vs. 68.9% (42/61), P < 0.05]. The nomogram calibration curve for predicting colorectal cancer constructed based on the combined detection of gene methylation and each clinical feature showed a high degree of concordance between the predicted and observed diagnostic performance of colorectal cancer. Conclusions:The methylation levels of SDC2, PPP2R5C AND ADHFE1 genes in stool are increased in patients with colorectal cancer or adenoma. The combined detection of gene methylation is expected to be a non-invasive method for the screening of colorectal cancer and precancerous lesions.
10.Meta-analysis of efficacy and safety of CDK4/6 inhibitor combined with endocrine in the treatment of HR+/HER2- breast cancer
Congcong HUANG ; Jing PENG ; Xunli XIAO ; Xuezhen HE
China Pharmacy 2023;34(22):2787-2792
OBJECTIVE To evaluate the efficacy and safety of four cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (dalpicilib, abemacilib, ribocilib, palbocilib) combined with endocrine drugs in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. METHODS Computer searches were conducted on PubMed, the Cochrane Library, Web of Science, Embase, CNKI, Wanfang data and VIP to collect randomized controlled trials (RCTs) about CDK4/6 inhibitors combined with endocrine drugs (trial group) versus endocrine drugs alone or combined with placebo (control group). The search period was from the establishment of the database to April 2023. After literature screening, data extraction and quality evaluation, a meta-analysis was conducted by using RevMan 5.4.1 software. RESULTS A total of 22 articles were included, involving 15 RCTs with a total of 18 574 patients. The meta-analysis results showed that the progression free survival [HR=0.77, 95%CI (0.74, 0.79), P<0.000 1], overall survival [HR=0.91, 95%CI (0.87, 0.94), P<0.000 01], objective response rate [OR=1.71, 95%CI (1.51, 1.93), P<0.000 01] and clinical benefit rate [OR=1.73, 95%CI (1.52, 1.95), P<0.000 01] of the trial group were significantly better than control group. The incidence of adverse drug reactions≥3 levels [OR=10.28,95%CI (6.97,15.17),P<0.000 01], neutropenia [OR=65.09, 95%CI (36.43, 116.31), P<0.000 01], leukopenia [OR=22.90, 95%CI (15.40, 34.04), P<0.000 01], anemia [OR=5.71, 95%CI (4.51, 7.22), P<0.000 01], diarrhea [OR= 3.00, 95%CI (1.19, 7.51), P<0.05] and nausea [OR=1.99, 95%CI (1.52, 2.60), P<0.000 01] in the trial group was significantly higher than control group. CONCLUSIONS The combination of CDK4/6 inhibitors and endocrine drugs has a significant effect on HR+/HER2- breast cancer, with a high incidence of adverse reactions, especially hematotoxicity.